QHSLab, Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results
QHSLab Inc. (OTCQB: USAQ) reported strong preliminary, unaudited financial results for Q4 and FY 2024. Q4 revenue increased 98% year-over-year to $625,981, with gross margin expanding to 65.8%. The company achieved net income of $40,838 in Q4, compared to a net loss of $86,627 in Q4 2023.
For full-year 2024, revenue grew 51% to $2.1 million, with improved gross margin of 63.7%. The company recorded its first profitable year with net income of $69,188, compared to a loss of $468,362 in 2023. Cash flow from operations was $247,317, resulting in net positive cash flow of $105,586. The company strengthened its balance sheet by repaying $298,531 in loans.
QHSLab Inc. (OTCQB: USAQ) ha riportato risultati finanziari preliminari, non verificati, molto positivi per il quarto trimestre e l'anno fiscale 2024. Le entrate del quarto trimestre sono aumentate del 98% rispetto all'anno precedente, raggiungendo $625,981, con un margine lordo che è salito al 65,8%. L'azienda ha registrato un reddito netto di $40,838 nel quarto trimestre, rispetto a una perdita netta di $86,627 nel quarto trimestre 2023.
Per l'intero anno 2024, le entrate sono cresciute del 51% a $2,1 milioni, con un margine lordo migliorato del 63,7%. L'azienda ha registrato il suo primo anno profittevole con un reddito netto di $69,188, rispetto a una perdita di $468,362 nel 2023. Il flusso di cassa dalle operazioni è stato di $247,317, con un flusso di cassa netto positivo di $105,586. L'azienda ha rafforzato il suo bilancio rimborsando $298,531 in prestiti.
QHSLab Inc. (OTCQB: USAQ) informó resultados financieros preliminares, no auditados, muy sólidos para el cuarto trimestre y el año fiscal 2024. Los ingresos del cuarto trimestre aumentaron un 98% interanual, alcanzando $625,981, con un margen bruto que se expandió al 65.8%. La compañía logró un ingreso neto de $40,838 en el cuarto trimestre, en comparación con una pérdida neta de $86,627 en el cuarto trimestre de 2023.
Para el año completo 2024, los ingresos crecieron un 51% hasta $2.1 millones, con un margen bruto mejorado del 63.7%. La compañía registró su primer año rentable con un ingreso neto de $69,188, en comparación con una pérdida de $468,362 en 2023. El flujo de caja de las operaciones fue de $247,317, resultando en un flujo de caja neto positivo de $105,586. La compañía fortaleció su balance al pagar $298,531 en préstamos.
QHSLab Inc. (OTCQB: USAQ)는 2024년 4분기 및 회계연도에 대한 강력한 예비 감사되지 않은 재무 결과를 보고했습니다. 4분기 매출은 전년 대비 98% 증가하여 $625,981에 달했으며, 총 마진은 65.8%로 확대되었습니다. 회사는 4분기에 $40,838의 순이익을 달성했으며, 이는 2023년 4분기의 $86,627 순손실과 비교됩니다.
2024년 전체 연도 매출은 51% 증가한 $2.1백만에 이르렀으며, 총 마진은 63.7%로 개선되었습니다. 회사는 2023년의 $468,362 손실과 비교하여 $69,188의 순이익을 기록하며 첫 번째 수익성 있는 해를 맞이했습니다. 운영으로부터의 현금 흐름은 $247,317였으며, 순 현금 흐름은 $105,586의 긍정적인 결과를 보였습니다. 회사는 $298,531의 대출을 상환하여 재무 상태를 강화했습니다.
QHSLab Inc. (OTCQB: USAQ) a annoncé des résultats financiers préliminaires et non audités très solides pour le quatrième trimestre et l'exercice 2024. Les revenus du quatrième trimestre ont augmenté de 98 % par rapport à l'année précédente, atteignant 625 981 $, avec une marge brute s'élevant à 65,8 %. L'entreprise a enregistré un bénéfice net de 40 838 $ au quatrième trimestre, contre une perte nette de 86 627 $ au quatrième trimestre 2023.
Pour l'année complète 2024, les revenus ont augmenté de 51 % pour atteindre 2,1 millions de dollars, avec une marge brute améliorée de 63,7 %. L'entreprise a enregistré sa première année bénéficiaire avec un bénéfice net de 69 188 $, contre une perte de 468 362 $ en 2023. Le flux de trésorerie provenant des opérations s'élevait à 247 317 $, entraînant un flux de trésorerie net positif de 105 586 $. L'entreprise a renforcé son bilan en remboursant 298 531 $ de prêts.
QHSLab Inc. (OTCQB: USAQ) berichtete über starke vorläufige, ungeprüfte Finanzzahlen für das vierte Quartal und das Geschäftsjahr 2024. Der Umsatz im vierten Quartal stieg im Jahresvergleich um 98% auf $625,981, während die Bruttomarge auf 65,8% anstieg. Das Unternehmen erzielte im vierten Quartal einen Nettogewinn von $40,838, verglichen mit einem Nettverlust von $86,627 im vierten Quartal 2023.
Für das gesamte Jahr 2024 wuchs der Umsatz um 51% auf $2,1 Millionen, mit einer verbesserten Bruttomarge von 63,7%. Das Unternehmen verzeichnete sein erstes profitables Jahr mit einem Nettogewinn von $69,188, verglichen mit einem Verlust von $468,362 im Jahr 2023. Der Cashflow aus dem operativen Geschäft betrug $247,317, was zu einem positiven Nettocashflow von $105,586 führte. Das Unternehmen stärkte seine Bilanz, indem es $298,531 an Krediten zurückzahlte.
- Revenue growth of 98% YoY in Q4 2024 to $625,981
- Full-year revenue increase of 51% to $2.1 million
- Gross margin improvement to 65.8% in Q4 and 63.7% for full year
- First profitable year with net income of $69,188
- Positive operating cash flow of $247,317
- Debt reduction of $298,531
- None.
- Four consecutive quarters of year-over-year revenue growth underscore continued business momentum.
- Revenue surges
98% in Q4 2024 compared to Q4 2023, marking a milestone year for QHSLab. - Operational efficiencies and strategic execution drive first profitable year.
WEST PALM BEACH, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its preliminary, unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024.
For the full year 2024, the Company recorded record revenue growth, substantial gross margin improvements, its first-ever year of profitability on a GAAP basis and positive cash flow from operations, which enabled it to repay a portion of its outstanding debt strengthening its balance sheet.
Financial Highlights:
- Fourth Quarter 2024 Preliminary Financial Results:
- Revenue surged
98% year-over-year to$625,981 , compared to$315,020 in Q4 2023, marking four consecutive quarters of year-over-year revenue growth. - Gross profit increased
117% to$412,154 , with gross margin expanding to65.8% , up from60.3% in the prior-year quarter. - Net income for Q4 2024 of
$40,838 , a significant improvement from a net loss of$86,627 in Q4 2023.
- Revenue surged
- Full-Year 2024 Preliminary Financial Results:
- Revenue grew
51% year-over-year, reaching$2.1 million compared to$1.4 million for the full-year 2023. - Gross margin improved to
63.7% , reflecting an enhanced product mix and increased operational efficiencies. - The Company recorded net income of
$69,188 for 2024, compared to a net loss of$468,362 in 2023, underscoring QHSLab’s strong financial momentum and commitment to profitable operations. - Positive Cash Flow Generation: The Company reported net positive cash flow of
$105,586 , driven by$247,317 in cash flow from operations, reflecting strong business performance. This was partially offset by a$141,731 net cash outflow from financing activities, which includes debt repayments and other financial obligations. - Continued Debt Reduction: The Company repaid
$298,531 in loans, further strengthening its balance sheet and reducing financial liabilities, reinforcing its commitment to long-term financial stability.
- Revenue grew
Management Commentary:
“These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions,” said Troy Grogan, President and CEO of QHSLab. “We are thrilled to report
Audit Status and Future Outlook:
The Company is currently finalizing its independent year-end audit in preparation for filing its Annual Report on Form 10-K prior to the 2024 SEC reporting deadline. While these financial results remain unaudited and are subject to change, management is confident in the reported numbers and expects only minor adjustments, if any.
“We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders,” added Troy Grogan. “With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.”
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
646-536-7331
https://twitter.com/QHSLabInc
FAQ
What was USAQ's revenue growth in Q4 2024?
How much debt did USAQ repay in 2024?
What was USAQ's net income for full-year 2024?
What was USAQ's gross margin in Q4 2024?
How much operating cash flow did USAQ generate in 2024?
